Small molecules that enhance or disrupt the interaction between NLRC4 and its interacting proteins represent a promising strategy to target NLRC4-mediated pathways in contexts such as cancers, infectious diseases, and autoinflammatory disorders. This evidence concerns the gene NLRC4 and infectious disease.